| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Levosalbutamol (also known as levalbuterol), the R-enantiomer of racemic salbutamol (albuterol), is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Salbutamol has been sold as a racemic mixture even though the (R)-enantiomer has nearly all of the beta2-agonist activity. Levosalbutamol (levalbuterol) is an enantiomerically pure (R)-salbutamol formulation that was developed in response to salbutamol's enantioselective disposition and the potential for negative effects associated with (S)-salbutamol.
| ln Vitro |
Levalbuterol hydrochloride (10 μM; 24 hours) causes 11β-HSD1 mRNA expression in airway epithelial cells, but not 11β-HSD2 expression[1].
Levalbuterol (10 μM; 24 hours) hydrochloride decreases NF-κB activity induced by TNF-α and LPS significantly while increasing GRE activation in a manner dependent on 11β-HSD1 in a transformed mouse airway epithelial cell line[1]. |
|---|---|
| ln Vivo |
Levalbuterol hydrochloride (subcutaneous injection; 1 mg/kg; 14 days) dramatically reduces pulmonary inflammation in OVA mice, as evidenced by a drop in IgE and eosinophilia[2].
|
| Cell Assay |
Cell Line: Murine Club (MTCC) cells
Concentration: 10 μM Incubation Time: 24 hours Result: Increased 11β-HSD1 mRNA expression selectively. |
| Animal Protocol |
C57BL/6 female mice with a pulmonary allergic model
1 mg/kg Subcutaneous injection; 1 mg/kg; 14 days |
| References |
| Molecular Formula |
C13H22CLNO3
|
|---|---|
| Molecular Weight |
275.77
|
| Exact Mass |
275.13
|
| Elemental Analysis |
C, 56.62; H, 8.04; Cl, 12.85; N, 5.08; O, 17.40
|
| CAS # |
50293-90-8
|
| Related CAS # |
Levalbuterol tartrate; 661464-94-4; Levalbuterol; 34391-04-3; 50293-90-8(HCl)
|
| Appearance |
Solid powder
|
| SMILES |
CC(C)(C)NC[C@@H](C1=CC(=C(C=C1)O)CO)O.Cl
|
| InChi Key |
OWNWYCOLFIFTLK-YDALLXLXSA-N
|
| InChi Code |
InChI=1S/C13H21NO3.ClH/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15;/h4-6,12,14-17H,7-8H2,1-3H3;1H/t12-;/m0./s1
|
| Chemical Name |
4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;hydrochloride
|
| Synonyms |
Levalbuterol HCl; Levosalbutamol HCl; Xopenex; (R)-albuterol; R-albuterol; R albuterol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ~100 mg/mL (~362.6 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (362.62 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6262 mL | 18.1311 mL | 36.2621 mL | |
| 5 mM | 0.7252 mL | 3.6262 mL | 7.2524 mL | |
| 10 mM | 0.3626 mL | 1.8131 mL | 3.6262 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00665600 | Completed | Drug: Levalbuterol HCl Drug: Albuterol Sulfate Drug: Placebo |
Chronic Obstructive Pulmonary Disease (COPD) |
Sumitomo Pharma America, Inc. | February 2002 | Phase 3 |
| NCT00667797 | Completed | Drug: levalbuterol HCl Drug: albuterol Sulfate |
Asthma COPD |
Sumitomo Pharma America, Inc. | March 2003 | Phase 4 |
| NCT00667407 | Recruiting | Drug: Levalbuterol 1.25 mg Drug: Racemic Albuterol Sulfate |
Asthma | Sumitomo Pharma America, Inc. | November 2000 | Phase 3 |
| NCT01076322 | Not yet recruiting | Drug: Meptin® Swinghaler Drug: Ventolin® MDI |
Asthma | Taiwan Otsuka Pharm. Co., Ltd | March 2009 | Phase 3 |
| NCT00583947 | Not yet recruiting | Drug: arformoterol Drug: levalbuterol |
Asthma | Sumitomo Pharma America, Inc. | January 2008 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA